Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

MLA

Jan Hendrik Rüschoff, et al. Expression of Phosphorylated Ribosomal Protein S6 in Mesothelioma Patients - Correlation with Clinico-Pathological Characteristics and Outcome: Results from the European Thoracic Oncology Platform (ETOP) Mesoscape Project. Dec. 2022. EBSCOhost, https://doi.org/10.1038/s41379-022-01145-0.

APA

Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, Sotirios Tsimpoukis, Steven G. Gray, Luca Ampollini, Joachim G. Aerts, Emanuela Felley-Bosco, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samarzija, Roger Llatjos, Stephen P. Finn, … Joachim Aerts. (2022). Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. https://doi.org/10.1038/s41379-022-01145-0

Chicago

Jan Hendrik Rüschoff, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, et al. 2022. “Expression of Phosphorylated Ribosomal Protein S6 in Mesothelioma Patients - Correlation with Clinico-Pathological Characteristics and Outcome: Results from the European Thoracic Oncology Platform (ETOP) Mesoscape Project,” December. doi:10.1038/s41379-022-01145-0.